Nurix Therapeutics (NRIX) Jefferies Global Healthcare Conference 2025 summary

Clinical program updates

• Bexdeg (NX-5948) phase 1A data will be presented at EHA, with phase 1B data expected by year-end, completing phase 1 disclosure.

• Regulatory and pivotal study plans for phase 2 and 3 in CLL will be formally updated mid-year, incorporating FDA feedback on design and dose.

• Dose selection for pivotal studies will be based on early data and agency input, with both 200mg and 600mg showing similar efficacy and safety.

• Active comparator for the confirmatory phase 3 CLL study is under discussion, with disclosure expected in Q3.

• Updates on indolent and aggressive NHL cohorts show strong activity, with CLL prioritized for development.

Expansion into autoimmune and inflammatory indications

• BTK degrader rationale includes targeting severe, high unmet need diseases with rapid, objective readouts and meaningful market size.

• Cohort in CLL patients with warm autoimmune hemolytic anemia (WHA) is open; timing of data disclosure depends on enrollment.

• IND for non-oncology autoimmune indications is targeted for end of this year or early next year.

• No formal plans yet for ITP, but it is considered a related indication for future basket trials.

• BTK degrader offers potential safety and efficacy advantages over inhibitors, including lower required drug levels and broader protein function elimination.

Pipeline and partnership highlights

• STAT6 degrader (NX-3911) advanced to development candidate status in partnership with Sanofi, who will fund IND-enabling and early clinical studies.

• Sanofi's option to co-develop post-proof-of-concept allows for a 50/50 US profit share, providing significant future economic potential.

• Preclinical data for NX-3911 show gene knockout-level STAT6 degradation and strong efficacy in animal models.

• Gilead-partnered IRAK4 degrader program has IND accepted and is entering healthy volunteer studies, with data expected in 2026.

• Cbl-b inhibitor (1607) phase 1A dose exploration is concluding, with over 60 patients enrolled across 11 solid tumors; data update anticipated this year.